Fresenius

October 05

October 05, 2023
Madrid, Spain

Berenberg Madrid Seminar

Presentation Import (ICS)
  • Robert Möller appointed to the Fresenius Management Board; at the same time, Möller will assume responsibility for hospital group as CEO of Helios Health GmbH
  • Dr. Francesco De Meo leaves the company
  • Management Board team continues to drive forward transformation on the way to #FutureFresenius


The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect. At the same time, he will take over as Chairman of the Management Board of Helios Health GmbH. He succeeds Dr. Francesco de Meo (59), who will leave the company.

Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master's degree in health care management, he switched to hospital management while continuing to work as a physician.

"Robert Möller, a physician and proven hospital manager from within the company will now move up to the Management Board. His experience is an excellent addition to the management team. With the further development of the hospital business, he will make an important contribution on the successfully chosen path to #FutureFresenius," said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius.

"Today, Fresenius is a company with a clear focus and clear responsibilities. We will continue to work together to execute our #FutureFresenius strategy and are well positioned to deliver. Robert Möller addresses the future of healthcare like almost no one else – with a clear focus on digitalization, sustainability and quality. At Helios, he will build on and drive the momentum we have generated so far with #FutureFresenius," said Fresenius CEO Michael Sen.

Helios is Europe's leading private healthcare provider, with approximately 126,000 employees. Together with Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics, Helios Group in Germany is part of the holding Helios Health. With more than 24 million patients per year, the company generated total sales of around 11.7 billion euros in 2022.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Dr. Sebastian Biedenkopf, Helen Giza, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch

The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect.
Download Image (JPG 687KB)
  • Robert Möller appointed to the Fresenius Management Board; at the same time, Möller will assume responsibility for hospital group as CEO of Helios Health GmbH 
  • Dr. Francesco De Meo leaves the company 
  • Management Board team continues to drive froward transformation on the way to #FutureFresenius

The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect. At the same time, he will take over as Chairman of the Management Board of Helios Health GmbH. He succeeds Dr. Francesco de Meo (59), who will leave the company.

Robert Möller has been CEO of Helios Kliniken GmbH since 2022. He joined Helios in 2014, where he held the position of Clinic Managing Director at Helios Hanseklinikum Stralsund until 2017. After a short time away, he returned to Helios in 2019 and took over the management of various regions. Möller studied human medicine at the University of Hamburg and practiced as a specialist for internal medicine. After various medical positions and a part-time master's degree in health care management, he switched to hospital management while continuing to work as a physician.

"Robert Möller, a physician and proven hospital manager from within the company will now move up to the Management Board. His experience is an excellent addition to the management team. With the further development of the hospital business, he will make an important contribution on the successfully chosen path to #FutureFresenius," said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius.

"Today, Fresenius is a company with a clear focus and clear responsibilities. We will continue to work together to execute our #FutureFresenius strategy and are well positioned to deliver. Robert Möller addresses the future of healthcare like almost no one else – with a clear focus on digitalization, sustainability and quality. At Helios, he will build on and drive the momentum we have generated so far with #FutureFresenius," said Fresenius CEO Michael Sen.

Helios is Europe's leading private healthcare provider, with approximately 126,000 employees. Together with Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics, Helios Group in Germany is part of the holding Helios Health. With more than 24 million patients per year, the company generated total sales of around 11.7 billion euros in 2022.
 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. 
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Dr. Sebastian Biedenkopf, Helen Giza, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
 

Activated carbon filters are used, which are attached to the anesthesia machine in the operating room or to the ventilator in the intensive care unit – exactly where the exhaust hose for the anesthetic gas is otherwise attached.

The substance that provides patients with a gentle and safe sleep during anesthesia causes up to 35 percent of all hospital emissions: this is the current reality of anesthetic gas.

(Published: July 2023)

Until now, the exhaled gases have been collected from the anesthesia machine and released into the outside air. Anesthetic gases thus promote the greenhouse effect and are among the worst climate killers worldwide. At Fresenius Helios’ 19 hospitals in the eastern region, a new filter system is now being used to recycle these gases. More than 90 percent of the anesthetic gases collected will thus be recycled in the future. 

With a consumption of more than 1,200,000 ml of inhalation anesthetics at the 19 clinics in the Helios Region East alone, recycling will save a CO2 equivalent of more than 1,100 tons per year in the future. This is comparable to driving almost five million kilometers in a mid-range gasoline-powered car: more than twelve times from the earth to the moon or 120 times around the equator.

Activated carbon filters are used, which are attached to the anesthesia machine in the operating room or to the ventilator in the intensive care unit – exactly where the exhaust hose for the anesthetic gas is otherwise attached. The gases are captured in these filters and most of them are recycled before they are used again for anesthesia – in line with sustainable recycling management principles. But the filter system not only pays off for the environment. It also reduces costs by eliminating the need for maintenance of the anesthetic gas extraction system. In addition, significant electricity savings can be achieved.

The gases are captured in these filters and most of them are recycled before they are used again for anesthesia.

After the trial in the 19 hospitals in the eastern region, Helios will decide whether to implement the project in the other regions in Germany. If all Helios hospitals were to use the new filter system, a CO2 equivalent of around 5,200 tons could be saved in the future. This is equivalent to driving 22,700,000 kilometers with a mid-range gasoline engine. Or put another way, that's 59 times the distance from the earth to the moon.

In addition, Helios has decided to stop using nitrous oxide, which is particularly harmful to the environment. In addition, the emission of the remaining anesthetic gases is reduced as much as possible by intelligently reducing the gas supply to the anesthesia device. For example, the use of desflurane, another very climate-damaging gas, has already been reduced by 40 percent. 

According to estimates by the German Society for Anesthesiology and Intensive Care Medicine, 17 million anesthesia procedures are performed in German hospitals each year. Added to this are many thousands more anesthesia procedures in the outpatient sector. Each anesthetic emits up to 118 kilograms of CO2 equivalents.

At Fresenius, we believe we have a responsibility to protect the environment and are striving for climate neutrality by 2040 as part of #FutureFresenius. That’s why we continually implement measures that help reduce our emissions.
 

Contact

Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Deutschland
T +49 30 521 321-0

www.helios-gesundheit.de

The rating agency Fitch today revised the outlook of Fresenius from negative to stable. The rating was affirmed at BBB-. The improved outlook is based on the consistent performance of the Operating Companies, a prudent capital allocation and progress on the group simplification, amongst others. The revised outlook is another strong testament of the successful execution of the strategy towards #FutureFresenius. Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA.

The rating agency Fitch today revised the outlook of Fresenius from negative to stable. The rating was affirmed at BBB-. The improved outlook is based on the consistent performance of the Operating Companies, a prudent capital allocation and progress on the group simplification, amongst others. The revised outlook is another strong testament of the successful execution of the strategy towards #FutureFresenius. Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi®HD with GuideMe Software, a completely reinvented self-guided interface for the company’s VersiHD chronic home hemodialysis (HHD) system. VersiHD with GuideMe Software aims to transform the experience of HHD for patients and nurses.

As the established leader in HHD, NxStage from Fresenius Medical Care, draws on its experience of over 30 million patient treatments at home over nearly two decades, serving patients in more than 45,000 homes with a broad diversity of water sources across the U.S.

VersiHD with GuideMe Software provides graphical walk-through guidance that aims to enhance ease of use and confidence for both patients and nurses. It is designed to improve patient training time, ease the transition to home, and make the training experience easier for new users.

“With over 13,000 HHD patients in the U.S. alone, we are excited to amplify the innovation NxStage offers with advanced technologies, like VersiHD with GuideMe Software,” said Dr. Katarzyna Mazur-Hofsäß, CEO of Fresenius Medical Care’s Care Enablement segment. “We are committed to providing cutting-edge solutions to improve the health and well-being of dialysis patients by challenging the standard of home dialysis with the design of industry-leading products.”

“We expect VersiHD with GuideMe Software to further simplify home hemodialysis for patients during training and at home,” said Dr. Brigitte Schiller, Senior Vice President, Medical Officer, Home Therapies at Fresenius Medical Care. “As a result of this software upgrade, patients and their care partners will have additional support to be confident with the therapy at home.  VersiHD with GuideMe Software will support Fresenius Medical Care’s mission of advancing access to home therapies to more patients.”

NxStage has had many significant innovations over the years guided by patient input starting with the first portable HHD machine, NxStage System One™, in 2005 followed by the introduction of the PureFlow™ DI Water Purification System in 2006. Nx2me Connected Health®, the first Connected Health platform for HHD followed in 2014. The NxStage System One was the first machine to receive FDA clearance for Nocturnal HHD indication in 2014 and also the first to receive FDA clearance for Solo HHD indication in 2017. In 2017, NxStage introduced the VersiHD touchscreen cycler. Over 95% of HHD patients in the U.S. use the NxStage HHD system.

VersiHD with GuideMe Software will initially be available in selected markets in 2023. Existing VersiHD systems will be upgradeable to GuideMe Software. For more information about VersiHD with GuideMe Software, please visit www.nxstage.com/hcp/versihdguideme.

Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

© 2023 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, NxStage, the triangle logo, VersiHD, PureFlow and Nx2me are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.


Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
 

Subscribe to